Suppr超能文献

恶性胸膜间皮瘤患者中 DNA 损伤修复相关种系新突变。

Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.

机构信息

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

J Thorac Oncol. 2020 Apr;15(4):655-660. doi: 10.1016/j.jtho.2019.12.111. Epub 2019 Dec 28.

Abstract

INTRODUCTION

Although next-generation sequencing (NGS) has brought insight into critical mutations or pathways (e.g., DNA damage sensing and repair) involved in the etiology of many cancers and has directed new screening, prevention, and therapeutic approaches for patients and families, it has only recently been used in malignant pleural mesotheliomas (MPMs).

METHODS

We analyzed the blood samples from patients with MPM using the NGS platform MSK-IMPACT to explore cancer-predisposing genes. The loss-of-function variants or pathogenic entries were identified, and clinicopathologic information was collected.

RESULTS

Of 84 patients with MPM, 12% (10 of 84) had pathogenic variants. Clinical characteristics were similar between cohorts, although patients with germline pathogenic variants were more likely to have more than two first-degree family members with cancer than those without germline mutations (40% versus 12%; Fisher's exact test, p < 0.05). Novel, deleterious variants in mesotheliomas included MutS homolog 3 (1% [one of 84]; 95% confidence interval [CI]: 0%-7%), breast cancer gene 1-associated ring domain 1 (1% [one of 84]; 95% CI: 0%-7%), and RecQ-like helicase 4 (2% [two of 84]; 95% CI: 0%-9%). Pathogenic variants previously reported on germline testing in patients with mesotheliomas were breast cancer gene 1-associated protein 1 (4% [three of 84]; 95% CI: 1%-10%), breast cancer gene 2 (1% [one of 84]; 95% CI: 0%-7%), and MRE11 homolog, double strand break repair nuclease (1% [one of 84]; 95% CI: 0%-7%). One patient (1% [one of 84]; 95% CI: 0%-7%) had a likely pathogenic alteration in SHQ1, H/ACA ribonucleoprotein assembly factor that has not been associated with a heritable susceptibility to cancer.

CONCLUSIONS

Our study lends further support for the role of aberrations in DNA damage repair genes in the pathogenesis of MPMs and suggests that targeting the members of these pathways for screening and treatment warrants further study.

摘要

简介

尽管下一代测序(NGS)已经深入了解了许多癌症发病机制中涉及的关键突变或途径(例如,DNA 损伤感应和修复),并为患者和家庭指导了新的筛查、预防和治疗方法,但它直到最近才被应用于恶性胸膜间皮瘤(MPM)。

方法

我们使用 NGS 平台 MSK-IMPACT 分析了 MPM 患者的血液样本,以探索致癌易感基因。鉴定了功能丧失性变异或致病性条目,并收集了临床病理信息。

结果

在 84 名 MPM 患者中,有 12%(10/84)存在致病性变异。两组患者的临床特征相似,尽管携带种系致病性变异的患者比没有种系突变的患者更有可能有两个以上一级亲属患有癌症(40%比 12%;Fisher 精确检验,p<0.05)。间皮瘤中发现的新的、有害的变异包括 MutS 同源物 3(1%[84 例中的 1 例];95%置信区间[CI]:0%-7%)、乳腺癌基因 1 相关环域 1(1%[84 例中的 1 例];95%CI:0%-7%)和 RecQ 样解旋酶 4(2%[84 例中的 2 例];95%CI:0%-9%)。以前在 MPM 患者的种系检测中报告的致病性变异包括乳腺癌基因 1 相关蛋白 1(4%[84 例中的 3 例];95%CI:1%-10%)、乳腺癌基因 2(1%[84 例中的 1 例];95%CI:0%-7%)和 MRE11 同源物,双链断裂修复核酶(1%[84 例中的 1 例];95%CI:0%-7%)。1 名患者(1%[84 例中的 1 例];95%CI:0%-7%)存在 SHQ1 中可能的致病性改变,SHQ1 是一种尚未与遗传性癌症易感性相关的 H/ACA 核糖核蛋白组装因子。

结论

我们的研究进一步支持 DNA 损伤修复基因异常在 MPM 发病机制中的作用,并表明针对这些途径的成员进行筛查和治疗值得进一步研究。

相似文献

1
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
J Thorac Oncol. 2020 Apr;15(4):655-660. doi: 10.1016/j.jtho.2019.12.111. Epub 2019 Dec 28.
2
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
Cancer Lett. 2017 Oct 1;405:38-45. doi: 10.1016/j.canlet.2017.06.028. Epub 2017 Jul 4.
3
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
J Clin Oncol. 2018 Oct 1;36(28):2863-2871. doi: 10.1200/JCO.2018.78.5204. Epub 2018 Aug 16.
5
Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment.
Eur J Cancer. 2022 Mar;163:44-54. doi: 10.1016/j.ejca.2021.12.023. Epub 2022 Jan 13.
6
New pathogenic germline variants identified in mesothelioma.
Lung Cancer. 2023 May;179:107172. doi: 10.1016/j.lungcan.2023.03.008. Epub 2023 Mar 15.
7
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
J Thorac Oncol. 2019 Nov;14(11):1989-1994. doi: 10.1016/j.jtho.2019.07.002. Epub 2019 Jul 16.
8
Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Lung Cancer. 2015 Jan;87(1):77-9. doi: 10.1016/j.lungcan.2014.10.017. Epub 2014 Nov 6.
9
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
J Thorac Oncol. 2023 Sep;18(9):1146-1164. doi: 10.1016/j.jtho.2023.05.028. Epub 2023 Jun 16.
10
Germline genetic variants in men with prostate cancer and one or more additional cancers.
Cancer. 2017 Oct 15;123(20):3925-3932. doi: 10.1002/cncr.30817. Epub 2017 Jun 28.

引用本文的文献

1
Cellular defense mechanisms against asbestos fibers.
Front Public Health. 2025 May 14;13:1566473. doi: 10.3389/fpubh.2025.1566473. eCollection 2025.
3
Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Peritoneal Mesothelial Tumors.
Ann Surg Oncol. 2024 Nov;31(12):7973-7977. doi: 10.1245/s10434-024-16004-2. Epub 2024 Aug 21.
4
Targeting DNA Damage Response Deficiency in Thoracic Cancers.
Drugs. 2024 Sep;84(9):1025-1033. doi: 10.1007/s40265-024-02066-9. Epub 2024 Jul 13.
5
Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma.
Oncoscience. 2024 May 23;11:53-57. doi: 10.18632/oncoscience.605. eCollection 2024.
6
Targeted Approaches to Treatment of Pleural Mesothelioma: A Review.
JCO Precis Oncol. 2023 Sep;7:e2300344. doi: 10.1200/PO.23.00344.
7
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair.
Cancers (Basel). 2023 Aug 29;15(17):4309. doi: 10.3390/cancers15174309.
8
Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma.
JAMA Netw Open. 2023 Aug 1;6(8):e2327351. doi: 10.1001/jamanetworkopen.2023.27351.
10
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
J Thorac Oncol. 2022 Jul;17(7):873-889. doi: 10.1016/j.jtho.2022.03.014. Epub 2022 Apr 21.

本文引用的文献

1
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
J Thorac Oncol. 2019 Nov;14(11):1989-1994. doi: 10.1016/j.jtho.2019.07.002. Epub 2019 Jul 16.
2
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
CA Cancer J Clin. 2019 Sep;69(5):402-429. doi: 10.3322/caac.21572. Epub 2019 Jul 8.
3
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9008-9013. doi: 10.1073/pnas.1821510116. Epub 2019 Apr 11.
5
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
J Clin Oncol. 2018 Oct 30;36(35):JCO2018790352. doi: 10.1200/JCO.2018.79.0352.
6
BAP1 links metabolic regulation of ferroptosis to tumour suppression.
Nat Cell Biol. 2018 Oct;20(10):1181-1192. doi: 10.1038/s41556-018-0178-0. Epub 2018 Sep 10.
7
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
J Clin Oncol. 2018 Oct 1;36(28):2863-2871. doi: 10.1200/JCO.2018.78.5204. Epub 2018 Aug 16.
8
Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.
Nat Commun. 2017 Oct 20;8(1):1081. doi: 10.1038/s41467-017-01198-9.
9
BAP1 regulates IP3R3-mediated Ca flux to mitochondria suppressing cell transformation.
Nature. 2017 Jun 22;546(7659):549-553. doi: 10.1038/nature22798. Epub 2017 Jun 14.
10
Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis.
Am J Hum Genet. 2016 Aug 4;99(2):337-51. doi: 10.1016/j.ajhg.2016.06.015. Epub 2016 Jul 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验